This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.

Publications

Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension

International Journal of Molecular Sciences – August 2023

Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension

European Respiratory Journal – June 2022

TORREY, a Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Pulmonary Circulation – October 2021

Scientific Congresses

Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy

PHPN - Sept 2023

Effects of Inhaled Seralutinib on Right Ventricular-Pulmonary Arterial (RV-PA) Coupling and Right Heart Function in Pulmonary Arterial Hypertension (PAH)

PHPN - Sept 2023

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 TORREY Trial

PHPN - Sept 2023

See More

Seralutinib MOA Video

A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension

Targeting the underlying mechanisms of Pulmonary Arterial Hypertension

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.

program
discovery
phase 1
phase 2
phase 3
+

Seralutinib (GB002) –
Pulmonary Arterial Hypertension

Inhaled PDGFR, CSF1R, c-KIT inhibitor
Phase 3 ready

clinical trials

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Phase: Phase 3 Ready
Description: The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 on improving exercise capacity in this population.

View on ClinicalTrials.gov
collapse window

recent posters and publications

Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy

PHPN - Sept 2023

Effects of Inhaled Seralutinib on Right Ventricular-Pulmonary Arterial (RV-PA) Coupling and Right Heart Function in Pulmonary Arterial Hypertension (PAH)

PHPN - Sept 2023

view more publications